Re: Treatment may sometimes fuel cancer's spread - a compound called TGF-beta may be one of the causes


"Matti Narkia" <mna@xxxxxxxx> wrote in message
news:pigq131dhlvmbdvuv27ovahmu4ki5ghtcb@xxxxxxxxxx
On Wed, 11 Apr 2007 15:07:47 -0400, J <nexsw@nvalid,anon> wrote:

Matti Narkia wrote:

On Wed, 11 Apr 2007 17:02:30 +0300, Matti Narkia <mna@xxxxxxxx> wrote:


[snip]

Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A,
Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M.
Inhibition of growth and metastasis of mouse mammary carcinoma by
selective inhibitor of transforming growth factor-beta type I receptor
kinase in vivo.
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30.
PMID: 16857807 [PubMed - indexed for MEDLINE]
<http://clincancerres.aacrjournals.org/cgi/content/abstract/12/14/4315>

[snip]

Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell
JE, Pollock BH, Mundy GR, Sun LZ.
Inhibition of pulmonary and skeletal metastasis by a transforming
growth factor-beta type I receptor kinase inhibitor.
Cancer Res. 2006 Jul 1;66(13):6714-21.
PMID: 16818646 [PubMed - indexed for MEDLINE]
<http://cancerres.aacrjournals.org/cgi/content/abstract/66/13/6714>

[snip]

Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M,
Balmain A, Akhurst RJ, Korn WM.
Transforming growth factor-beta receptor inhibition enhances
adenoviral infectability of carcinoma cells via up-regulation of
Coxsackie and Adenovirus Receptor in conjunction with reversal of
epithelial-mesenchymal transition.
Cancer Res. 2006 Feb 1;66(3):1648-57.
PMID: 16452224 [PubMed - indexed for MEDLINE]
<http://cancerres.aacrjournals.org/cgi/content/full/66/3/1648>

[snip]

Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
Blockade of transforming growth factor-beta signaling suppresses
progression of androgen-independent human prostate cancer in nude
mice.
Clin Cancer Res. 2005 Jun 15;11(12):4512-20.
PMID: 15958637 [PubMed - indexed for MEDLINE]
<http://clincancerres.aacrjournals.org/cgi/content/full/11/12/4512>

[snip]

Shu XO, Gao YT, Cai Q, Pierce L, Cai H, Ruan ZX, Yang G, Jin F, Zheng
W.
Genetic polymorphisms in the TGF-beta 1 gene and breast cancer
survival: a report from the Shanghai Breast Cancer Study.
Cancer Res. 2004 Feb 1;64(3):836-9.
PMID: 14871809 [PubMed - indexed for MEDLINE]
<http://cancerres.aacrjournals.org/cgi/content/full/64/3/836>

[snip]

Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM.
TGF-beta switches from tumor suppressor to prometastatic factor in a
model of breast cancer progression.
J Clin Invest. 2003 Oct;112(7):1116-24.
PMID: 14523048 [PubMed - indexed for MEDLINE]
<http://www.jci.org/cgi/content/full/112/7/1116>

One more abstract:

Liu P, Menon K, Alvarez E, Lu K, Teicher BA.
Transforming growth factor-beta and response to anticancer therapies
in human liver and gastric tumors in vitro and in vivo.
Int J Oncol. 2000 Mar;16(3):599-610.
PMID: 10675495 [PubMed - indexed for MEDLINE]
<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=10675495>

--
Matti Narkia

<http://groups.google.tm/group/sci.med.prostate.cancer/msg/cc59e7640f385912?hl=en&;>

Spell out your point and arguments, J.


--
Matti Narkia

I think the bottom line would be: don't treat with radiation, surgery or
chemotherapy unless there is a well-defined benefit supported by evidence.
Often the best treatment is NO treatment


.

Relevant Pages
Loading